Rethinking transcription factors and gene expression

Study shows that, like proteins, genomes must fold appropriately to function properly and that some transcription factors provide the structural support.

Nicole Giese Rura | Whitehead Institute
December 7, 2017

Transcription — the reading of a segment of DNA into an RNA template for protein synthesis — is fundamental for nearly all cellular processes, including growth, responding to stimuli, and reproduction. Now, Whitehead Institute researchers have upended our understanding of how transcription is controlled and the role of transcription factors in the process.

The paradigm shift, described in an article online on Dec. 7 in the journal Cell, hinges on a small protein that plays a key role in genome structure and gives us new insights into how changes in the control of transcription and gene expression can lead to disease.

Transcription has several important players that must all be in the right place at the right time: the transcription machinery, transcription factors, promoters, and enhancers.  According to the existing model, transcription factors are proteins that bind to enhancer regions of the genome and recruit the transcription machinery to the promoter DNA regions, which then initiate the genes’ transcription.

“We’ve always assumed that the role of transcription factors was to recruit the transcription machinery to genes to turn them on or turn them off,” says Richard Young, a Whitehead Insistute member and professor of biology at MIT. “But we never imagined that the transcription factors we’ve studied for three decades actually contribute to the genome’s structure. And as a consequence, they regulate genes. So we now look at genomes like proteins: They have to fold up appropriately in order to control genes.”

Scientists have known that the genome’s structure — how it bends and folds — is essential for efficiently compressing two meters of DNA into each human cell, which is the equivalent of packing a strand ten football fields long into a space the size of a marble. Yet until recently, researchers have not had the tools necessary to appreciate this architecture’s importance in fine control of gene expression or study the genome’s structure at sites ready for transcription.

In 2014, Young and his lab determined that portions of the genome reside in loop-based structures, creating insulated neighborhoods that bring enhancers, promoters, and genes into close proximity. Each loop is tied at the top by a pair of molecules, called CTCF, that are bound together. This structure is essential for proper gene control: If the loop structure is broken, gene expression is altered, and cells can become diseased or die.

In the current research, Young along with co-first authors Abraham Weintraub and Charles Li took a closer look at a protein that is well known but not well understood: Yin Yang 1 (YY1). Hundreds of scientific papers have linked YY1 dysfunction to diseases such as viral infections, cancer, and arthritis, and yet the studies produced seemingly contradictory observations of YY1’s function.

According to Young and colleagues, YY1 is a unique transcription factor that occupies both enhancers and promoters, is essential for cell survival, and is found in almost every cell type in humans and mice. Like CTCF, YY1 can also pair with itself and bind to DNA to form loops that enhance DNA transcription.

“YY1 is expressed broadly, and it is necessary for establishing enhancer-promoter loops in multiple cell types,” says Weintraub. “That’s its job, not recruiting the transcription apparatus. When the structure created by YY1 is removed, the genome is no longer folded properly, gene control is lost and transcription of the affected genes is significantly diminished, which can cause dysfunction.”

This model of YY1’s function could account for its association with a number of disparate diseases. Earlier this year, scientists reported YY1 syndrome — a genetic syndrome causing cognitive disabilities in people with mutations in their YY1 gene.

According to Young, YY1 is probably not the only transcription factor with this loop-forming role, and his lab will be searching for additional factors with similar functions.

“YY1 is most likely just the first one, and there are probably a bunch of collaborators that have similar roles,” says Young. “Instead of the classic function that we thought these transcription factors had — interacting with the transcription apparatus and giving instructions on how much or how little of a gene’s transcript to produce — they are bringing together regulatory elements with the gene. The whole job of these transcription factors is just making structure. We are realizing that the things that form physical structures are much more important than we had appreciated.”

The researchers’ work was supported by the National Institutes of Health, the Ludwig Graduate Fellowship funds, the National Science Foundation, the American Cancer Society, a Margaret and Herman Sokol Postdoctoral Award, the Damon Runyon Cancer Research Foundation, and the Cancer Research Institute. The Whitehead Institute has filed a patent application based on this study.

Michael T. Laub

Education

  • PhD, 2002, Stanford University
  • BS, 1997, Molecular Biology, University of California, San Diego

Research Summary

We study the biological mechanisms and evolution of how cells process information to regulate their own growth and proliferation. Using bacteria as a model organism, we aim to elucidate the detailed molecular basis for this remarkable regulatory capability, and understand the selective pressures and mechanisms that drive the evolution of signaling pathways. Our work is rooted in a desire to develop a deeper, fundamental understanding of how cells function and evolve, but it also has important medical implications since many signaling pathways in pathogenic bacteria are needed for virulence.

Awards

  • Howard Hughes Medical Institute, HHMI Investigator, 2015
  • National Science Foundation, Presidential Early Career Award for Scientists and Engineers, 2010
  • Howard Hughes Medical Institute, Early Career Scientist, 2009
Graham C. Walker

Education

  • PhD, 1974, University of Illinois
  • BS, 1970, Chemistry, Carleton University

Research Summary

Our research is concentrated in two major areas. First, we aim to understand how the proteins involved in DNA repair, mutagenesis and other cellular responses to DNA damage are regulated. Some of our discoveries have the potential to improve chemotherapy. Second, we probe how nitrogen-fixing nodules develop on legumes, and the relationship between rhizobial functions required for nodule invasion/infection and mammalian pathogenesis.

Awards

  • Revolutionizing Innovative, Visionary Environmental health Research (RIVER), R35 Outstanding Investigator Award, 2017
  • National Academy of Sciences, Member, 2013
  • Howard Hughes Medical Institute, HHMI Professor, 2010
  • University of Guelph, Doctor of Science, honoris causa, 2010
  • American Association for the Advancement of Science, Fellow, 2008
  • Environmental Mutagen Society, EMS Award, 2006
  • American Academy of Arts and Sciences, Fellow, 2004
  • American Cancer Society, Research Professor, 2002
  • Howard Hughes Medical Institute, HHMI Professor, 2002
  • Charles Ross Scholar, 2000-2003
  • American Academy of Microbiology, Fellow, 1994
  • Margaret MacVicar Faculty Fellow, 1992-2002
  • John Simon Guggenheim Memorial Foundation, Guggenheim Fellowship, 1984
  • Massachusetts Institute of Technology, MacVicar Faulty Fellow, 1984
  • Rita Allen Foundation, Career Development Award, 1978
H. Robert Horvitz

Education

  • PhD, 1974, Harvard University
  • BS, 1968, Mathematics and Economics, MIT

Research Summary

Our lab examines how genes control animal development and behavior. We use the experimentally tractable nematode Caenorhabditis elegans to identify and analyze molecular and cellular pathways involved in these important areas of biology. Ultimately, we hope to clarify these fundamental biological mechanisms and provide further insight into human disease.

Awards

  • U.S. National Academy of Inventors, Member, 2015
  • American Association for Cancer Research Academy, Fellow, 2013
  • Royal Society of London, Foreign Member, 2009
  • Genetics Society (U.K.), Mendel Medal, 2007
  • Eli Lilly Lecturer Award, 2007
  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2006
  • National Academy of Medicine, Member, 2003
  • American Cancer Society, Medal of Honor, 2002
  • The Nobel Foundation, Nobel Prize in Physiology or Medicine, 2002
  • Bristol-Myers Squibb, Award for Distinguished Achievement in Neuroscience, 2001
  • March of Dimes, Developmental Biology, 2000
  • Gairdner Foundation, Gairdner Foundation International Award, 1999
  • National Academy of Sciences, Member, 1991
  • American Academy of Arts and Sciences, Fellow, 1989
  • American Association for the Advancement of Science, Fellow, 1989
  • Howard Hughes Medical Institute, HHMI Investigator, 1988
Peter Reddien

Education

  • PhD, 2002, MIT
  • SB, 1996, Molecular Biology, University of Texas at Austin

Research Summary

We investigate how stem cells are regulated to regenerate missing tissues. We study the cellular events involved in this process and the attendant roles for regulatory genes that control regeneration steps. We utilize an array of methodologies, including high-throughput sequencing, RNA interference (RNAi) screening, and numerous assays and tools for phenotypic analysis to characterize regeneration regulatory genes.

Awards

  • Howard Hughes Medical Institute, HHMI Investigator, 2013
David C. Page

Education

  • MD, 1984, Harvard Medical School
  • BS, 1978, Chemistry, Swarthmore College

Research Summary

We seek to understand the genetic differences between males and females — both within and beyond the reproductive tract. We study the medical ramifications of these differences in a broad context, through comparative biological, evolutionary, developmental and clinically focused analyses. Our three main veins of research relate to sex differences in health and disease, sex chromosome genomics, and germ cell origins and development.

Awards

  • American Academy of Arts and Sciences, Fellow, 2012
  • March of Dimes, Developmental Biology, 2011
  • National Academy of Medicine, Member, 2008
  • National Academy of Sciences, Member, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1990
  • MacArthur Foundation, MacArthur Fellowship, 1986
David Bartel

Education

  • PhD, 1993, Harvard University
  • BA, 1982, Biology, Goshen College

Research Summary

We study microRNAs and other small RNAs that specify the destruction and/or translational repression of mRNAs. We also study mRNAs, focusing on their untranslated regions and poly(A) tails, and how these regions recruit and mediate regulatory phenomena.

Awards

  • National Academy of Sciences, Member, 2011
  • Howard Hughes Medical Institute, HHMI Investigator, 2005
  • National Academy of Sciences Award in Molecular Biology, 2005
  • AAAS Newcomb Cleveland Prize, 2002
David Housman

Education

  • PhD, 1971, Brandeis University
  • BS, 1966, Biology, Brandeis University

Research Summary

We use genetic approaches to identify the molecular basis of human disease pathology. More specifically, we develop strategies to combat three major disease areas: cancer, trinucleotide repeat disorders like Huntington’s disease, and cardiovascular disease.

Awards

  • National Academy of Medicine, Member, 1997
  • National Academy of Sciences, Member, 1994
Leonard P. Guarente

Education

  • PhD, 1978, Harvard University
  • SB, 1974, Biology, MIT

Research Summary

We combine comprehensive bioinformatics analyses with functional analyses of pathways and genes to study aging in humans and mice. We apply these approaches to identify the major pathways and genes involved in the aging of certain brain regions. We are also studying muscular dystrophy and muscle loss with aging. Ultimately, our findings may guide studies in other organs and lead to a systemic understanding of mammalian aging.

Awards

  • Miami Winter Symposium, Feodor Lynen Award, 2012
  • University of Toronto, Charles H. Best Lectureship and Award, 2011
  • Dart/NYU Biotechnology, Achievement Award, 2009
  • French Academie des Sciences, Elected, 2009
  • American Academy of Arts and Sciences, Fellow, 2004
Tyler Jacks

Education

  • PhD, 1988, University of California, San Francisco
  • SB, 1983, Biology, Harvard University

Research Summary

Dr. Jacks’ research has focused on developing new methods for the construction and characterization of genetically engineered mouse models or GEMMs of human cancer, and recently has moved into the burgeoning area of tumor immunology to understand the interactions between the immune system and cancer.  His group has produced GEMMs with constitutive and conditional mutations in several tumor suppressor genes, oncogenes, and genes involved in oxidative stress, DNA repair and epigenetic control of gene expression. These GEMMS have been used to examine the mechanism of tumor initiation and progression, to uncover the molecular, genetic and biochemical relationship to the human diseases, as tools to study response and resistance to chemotherapy, and to explore methods in molecular imaging and early detection of cancer.

Awards

  • AACR Princess Takamatsu Memorial Lectureship, 2020
  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2015
  • Sergio Lombroso Award in Cancer Research, 2015
  • American Academy of Arts and Sciences, Fellow, 2012
  • National Academy of Sciences, Member, 2009
  • Institute of Medicine of the National Academies, Member, 2009
  • Paul Marks Prize for Cancer Research, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1994